Maximum Dosing of Neupogen (Filgrastim)
The maximum dose of Neupogen (filgrastim) for adults is 10 mcg/kg/day, which is used specifically for peripheral blood progenitor cell (PBPC) mobilization. For all other clinical settings including chemotherapy-induced neutropenia prophylaxis, the standard dose is 5 mcg/kg/day 1.
Dosing Framework by Clinical Indication
Standard Chemotherapy Support
- Dose: 5 mcg/kg/day subcutaneously 1
- Start 1-3 days after myelotoxic chemotherapy
- Continue until absolute neutrophil count (ANC) reaches 2-3 × 10⁹/L
- This is the recommended dose for preventing febrile neutropenia in cancer patients
Stem Cell Mobilization
- Dose: 10 mcg/kg/day subcutaneously 1
- This higher dose is preferable for PBPC mobilization
- Start 4 days before first leukapheresis
- Continue through last leukapheresis procedure
- Recent evidence confirms 10 mg/kg/day (whether given once daily or split into 5 mg/kg twice daily) achieves adequate CD34+ cell mobilization 2
High-Dose Therapy with Stem Cell Rescue
- Dose: 5 mcg/kg/day 1
- Can be started 1-5 days after high-dose therapy
- Continue until ANC recovery
Safety and Tolerability Data
The FDA label provides important context on maximum tolerated doses 3:
- No maximum tolerated dose has been formally established
- Patients in bone marrow transplant studies received up to 138 mcg/kg/day without toxic effects
- However, dose-response curve flattens above 10 mcg/kg/day, indicating no additional benefit
- White blood cell counts >100,000/mm³ occurred in <5% of patients but were not associated with adverse clinical effects
Key Clinical Considerations
Route of administration: Subcutaneous is the preferred route for all indications 1. Intravenous administration is possible but less commonly used.
Duration matters more than you might think: Continue filgrastim through all chemotherapy cycles rather than just initial cycles. Evidence shows stopping prophylaxis early (after 2 cycles vs. all 6 cycles) increases febrile neutropenia risk from 10% to 36% 1.
Common pitfall: Stopping filgrastim too early before adequate ANC recovery. The guideline specifies continuing until ANC reaches 2-3 × 10⁹/L, not just for a fixed number of days 1. Recent data suggests tracking post-nadir ANC is critical to prevent complications 4.
Practical dosing: Most patients receive a median of 7-8 doses per chemotherapy cycle 4. The typical duration is approximately one week, though this varies based on individual ANC recovery.
Biosimilar Equivalence
Filgrastim biosimilars (filgrastim-sndz, Nivestim) use identical dosing to original Neupogen 1, 5. The 5 mcg/kg and 10 mcg/kg maximum doses apply equally to biosimilar products.